Mumbai, Jan 21 :Laurus Labs Limited a leading research & development-driven, fully integrated pharmaceutical and biotech company Today said that it has signed an agreement with MPP (Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.

Commenting on the development, Dr Satyanarayana Chava, Founder and CEO, Laurus Labs said, “We are happy to sign an agreement to manufacture the oral Covid-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission.”(UNI)